Federal Register of Legislation - Australian Government

Primary content

PB 39 of 2012 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (No. PB 116 of 2010) to make changes to the special arrangement relating to the hightly specialised drugs program for hospitals.
Administered by: Health
Registered 29 Jun 2012
Tabling HistoryDate
Tabled HR14-Aug-2012
Tabled Senate14-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 39 of 2012

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2012 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, FELICITY MCNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated        29 June 2012

 

 

 

 

 

 

 

 

 

 

 

 

 

FELICITY MCNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________________

 

 

 

 


1              Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2012 (No.5).

 

(2)                This Instrument may also be cited as PB 39 of 2012.

 

2             Commencement

This Instrument commences on 1 July 2012.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

 

 


Schedule 1                   Amendments

[1]      Section 4, after definition for other Special Arrangement

insert:

paperless claim for payment has the meaning given in the Regulations.

 

[2]      Section 4, after definition for streamlined authority code

insert:

supply certification form has the meaning given in the Regulations.

 

[3]      After subsection 33(2)

insert:

(3)       Subregulation 31(4) of the Regulations does not apply to a paperless claim for payment submitted in accordance with this Subdivision.

Note Subregulation 31(4) provides that an approved supplier commits an offence if a paperless claim for payment is made and a completed supply certification form is not included.

 

[4]    Schedule 1, entry for Abatacept

omit from the column headed ‘Section 100 Only’:

D

substitute:

PB

 

[5]    Schedule 1, entry for Clozapine in the form Tablet 25 mg with manner of administration Oral and brand Clozaril 25

insert in the column headed ‘Section 100 Only’:

D

[6]    Schedule 1, entry for Clozapine in the form Tablet 100 mg with manner of administration Oral and brand Clozaril 100

insert in the column headed ‘Section 100 Only’:

D

 

[7]    Schedule 1, entry for Cyclosporin in the form Capsule 25 mg with manner of administration Oral and brand Neoral 25

insert in the column headed ‘Section 100 Only’:

C

 

[8]    Schedule 1, entry for Cyclosporin in the form Capsule 50 mg with manner of administration Oral and brand Neoral 50

insert in the column headed ‘Section 100 Only’:

C

 

[9]    Schedule 1, entry for Cyclosporin in the form Capsule 100 mg with manner of administration Oral and brand Neoral 100

insert in the column headed ‘Section 100 Only’:

C

 

[10]  Schedule 1, entry for Levodopa with Carbidopa

omit from the column headed ‘Section 100 Only’:

D

substitute:

C

 

[11]  Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 90 mg in 10 mL

omit from the column headed ‘Section 100 Only’:

C

substitute:

PB

 

[12]  Schedule 1, entry for Pamidronic Acid in the form Injection set containing 1 vial powder for I.V infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL

omit from the column headed ‘Section 100 Only’:

C

substitute:

PB

 

 

[13]  Schedule 1, entry for Zoledronic Acid

Omit from the column headed ’Circumstances’:

C3881 C3882

Insert after C3343:

C4051 C4052

 

[14]  Schedule 3, entry for Zoledronic Acid

omit:

 

C3881

 

Where the patient is receiving treatment at/from a private hospital

Bone metastases from hormone-resistant prostate cancer;

Compliance with Written or Telephone Authority Required procedures

substitute:

 

C4051

 

Where the patient is receiving treatment at/from a private hospital

Bone metastases from castration-resistant prostate cancer

Compliance with Written or Telephone Authority Required procedures

 

[15]  Schedule 3, entry for Zoledronic Acid

omit:

 

C3882

 

Where the patient is receiving treatment at/from a public hospital

Bone metastases from hormone-resistant prostate cancer

Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 3882

substitute:

 

C4052

 

Where the patient is receiving treatment at/from a public hospital

Bone metastases from castration-resistant prostate cancer

Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 4052

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.